Lanreotide acetate

Lanreotide acetate (BIM 23014 acetate) is a somatostatin analogue with antineoplastic activity. Lanreotide acetate can be used for carcinoid syndrome[1][2].

Research Areas >> Cancer

Research Areas >> Endocrinology

Signaling Pathways >> Others >> Others

Lanreotide acetate (BIM 23014 acetate) (24-48 hours; 100  nM; GH3 cells) combines with radiation increasing in apoptotic sub-G1 proportion[1]. Lanreotide acetate results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide acetate at doses of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 (50% inhibition of cell growth) was 57 nM[1]. Lanreotide acetate inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro[2].

Lanreotide acetate (2.5-10mg/kg; s.c.; daily for 5 days) resluts in tumor growth inhibition[1]. Animal Model: Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)[1] Dosage:  2.5, 5, 10 mg/kg Administration: Subcutaneous; daily for 5 days Result: Produced tumor growth inhibition.

[1]. Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55.

[2]. Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28.